Status:
UNKNOWN
Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome
Lead Sponsor:
Nanjing University
Conditions:
Adenomyosis
Assisted Reproductive Technology
Eligibility:
FEMALE
20-38 years
Phase:
NA
Brief Summary
In assisted reproductive technology, adenomyosis patients are characterized by lower clinical pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study is to explore ...
Eligibility Criteria
Inclusion
- The basal serum level of FSH was less than 10 IU / L
- Diagnosed with adenomyosis by ultrasound
- The first frozen thawed embryo transfer cycle, by hormone replacement protocol
- Transfer at least one high quality frozen embryo;
- Patients agreed to use low molecular weight heparin after FET, and they were able to sign informed consent in person.
Exclusion
- With abnormal karyotype;
- Accompanied with other uterine diseases: intrauterine adhesion, intramural myoma, moderate to severe endometriosis, congenital uterine malformation, endometrial tuberculosis, thin endometrium \< 8mm on the day of transformation, etc;
- PCOS, RIF patients;
- There are indications of conventional anticoagulation or antiplatelet therapy, such as antiphospholipid syndrome, autoimmune diseases, coagulation dysfunction, etc;
- There were contraindications to hormone replacement therapy and low molecular weight heparin;
- Participating in other clinical studies;
- Unable to follow-up
Key Trial Info
Start Date :
February 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04741295
Start Date
February 1 2020
End Date
January 31 2022
Last Update
February 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China, 210008